FTC Questions Apple News Over Alleged Bias Against Conservative Media 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
GAITHERSBURG, Md., Nov. 08, 2017 -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will present at the Stifel 2017 Healthcare Conference.
Presentation details are as follows:
Date: Wednesday, November 15, 2017
Time: 1:15 p.m. – 1:55 p.m. ET
Location: Garrison, 5th Floor, Lotte New York Palace Hotel, New York City
Live webcast: www.novavax.com, “Investors”/“Events”
A replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact:
Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor & Media Relations
[email protected]
240-268-2000
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Russo Partners, LLC
David Schull
Maggie Beller
[email protected]
[email protected]
212-845-4271
